Amid the changing landscape of treatments for ALK-positive NSCLC, sequencing of ALK inhibitors grows more complex and will require an assessment of individual patient’s tumor characteristics. Read More ›

Seribantumab (MM-121), a drug under investigation in the phase 2 SHERLOC trial for the treatment of heregulin-positive NSCLC, was granted orphan drug designation from the FDA. Read More ›

The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology have updated their 2013 molecular analysis guideline for the selection of patients with lung cancer for TKI treatment, to include 18 new recommendations and 3 revisions to the existing guidance. Read More ›

Based on results from the phase 3 FLAURA trial, the FDA has granted osimertinib (Tagrisso) breakthrough therapy designation for treatment-naïve patients with EGFR-positive non–small-cell lung cancer. Read More ›

In the pivotal phase 3 KEYNOTE-189 trial of pembrolizumab (Keytruda) combined with pemetrexed and cisplatin or carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small-cell lung cancer, the regimen showed significant improvements in overall survival and progression-free survival. Read More ›

The kinase inhibitor alectinib (Alecensa) received FDA approval for the frontline treatment of ALK-positive, metastatic, non–small-cell lung cancer based on results from the phase 3 ALEX trial. Read More ›

Although crizotinib is the standard of care for the first-line treatment of patients with ALK-positive non–small-cell lung cancer, disease progression occurs in most crizotinib-treated patients, often calling for the use of second-generation ALK inhibitors such as alectinib, brigatinib, and ceritinib, among other treatment strategies. Read More ›

Results from a phase 2 trial of lorlatinib, an investigational, next-generation tyrosine kinase inhibitor, showed efficacy in treating lung tumors and brain metastases in patients with ALK-positive and ROS1-positive advanced non–small-cell lung cancer, including those who have been heavily pretreated. Read More ›

Updated data from the phase 2 ALTA trial continue to support the efficacy and tolerability of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK), in patients with locally advanced or metastatic ALK-positive non–small-cell lung cancer (NSCLC) who have progressed while using crizotinib. Read More ›

Until the expanded approval of afatinib, no targeted treatment options were available for patients with non–small-cell lung cancer (NSCLC) who harbored rare, nonresistant EGFR mutations, such as S768I, L861Q, and G719X. Among oral tyrosine kinase inhibitors approved for use in EGFR mutation–positive NSCLC, afatinib now offers the broadest first-line indication. Read More ›